Literature DB >> 10233936

Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

D B Schowalter1, C L Himeda, B L Winther, C B Wilson, M A Kay.   

Abstract

This study explores the genetic and immunologic factors involved in the differences in duration of transgene expression following in vivo transduction with recombinant adenoviruses. Different strains of mice (C3H/HeJ [C3H], C57BL/6J [B6], BALB/cJ [Balb/c], C. B10-H2(b)/LiMcdJ [Balb.B], CB6F1/J [(Balb/c x B6)F1], B6C3F1/J [(B6 x C3H)F1], and BALB/cj SCID) received 5 x 10(9) PFU of the first-generation adenovirus, which expresses human alpha1-antitrypsin (Ad/RSVhAAT). While all strains studied showed similar patterns of anti-adenovirus antibody formation, only Balb/c and C3H mice developed significant levels of anti-hAAT antibodies by 8 weeks posttransduction. In addition, while all strains had quantitatively comparable amounts of adenovirus genomes and hAAT mRNA transcripts in the liver 9 days posttransduction, only Balb/c mice had undetectable adenovirus vector genomes and hAAT mRNA in the liver 40 days posttransduction. Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling staining of liver sections from control and Ad/RSVhAAT-infected mice 5, 9, and 40 days posttransduction suggested that apoptosis was involved in the rapid elimination of transduced hepatocytes in Balb/c mice. Persistent expression of hAAT protein observed in BALB/cj SCID mice suggests that antigen-dependent immunity was essential for this apoptotic process in transduced Balb/c hepatocytes. In contrast to Balb/c mice, the loss of expression in C3H mice did not correlate with the loss of vector genomes or hAAT mRNA. Instead, the anti-hAAT antibodies in C3H but not Balb/c mice were found to interfere with detection of hAAT in the serum. In Balb. B and B6 mice, vector genome, hAAT mRNA transcripts, and hAAT protein levels persisted for at least 40 days posttransduction. This persistence correlated with poor anti-hAAT antibody formation and minimal hepatocyte toxicity. The expression of hAAT in (Balb/c x B6)F1 pups was found to be intermediate between the duration observed in the parental strains, while in (C3H x B6)F1 pups hAAT expression was similar to that seen in the B6 parents, which together support polygenic control of the immune responses in these mice. In summary, these findings suggest that there are three different profiles and at least two defined immune system-mediated mechanisms resulting in the loss of hAAT expression in mice and that different strains differ in the capacity to utilize these mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233936      PMCID: PMC112518     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

Authors:  S Worgall; G Wolff; E Falck-Pedersen; R G Crystal
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

2.  Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver.

Authors:  S N Yao; A Farjo; B J Roessler; B L Davidson; K Kurachi
Journal:  Viral Immunol       Date:  1996       Impact factor: 2.257

3.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

4.  Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene.

Authors:  K F Kozarsky; K Jooss; M Donahee; J F Strauss; J M Wilson
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

5.  In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Authors:  M Lusky; M Christ; K Rittner; A Dieterle; D Dreyer; B Mourot; H Schultz; F Stoeckel; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer.

Authors:  M J Vrancken Peeters; A L Perkins; M A Kay
Journal:  Biotechniques       Date:  1996-02       Impact factor: 1.993

9.  CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40.

Authors:  Y Yang; J M Wilson
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

Authors:  S K Tripathy; H B Black; E Goldwasser; J M Leiden
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  9 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation.

Authors:  Y Peng; E Falck-Pedersen; K B Elkon
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

6.  Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo.

Authors:  Anja Ehrhardt; Hui Xu; Mark A Kay
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Improving adenovirus based gene transfer: strategies to accomplish immune evasion.

Authors:  Sergey S Seregin; Andrea Amalfitano
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

8.  Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System.

Authors:  Lalitha R Belur; Kelly M Podetz-Pedersen; Brent S Sorenson; Alice H Hsu; Josh B Parker; Cathy S Carlson; Daniel A Saltzman; S Ramakrishnan; R Scott McIvor
Journal:  Mol Cancer       Date:  2011-02-10       Impact factor: 27.401

9.  Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector.

Authors:  L Aurisicchio; H Bujard; W Hillen; R Cortese; G Ciliberto; N La Monica; F Palombo
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.